# Progress Note 04 — Sick Visit

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jesse Owens (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML042-SYN
- Date: 2026-07-06
- Fictional facility: St. Posthumous Health Center
- Fictional author: Clarence Whitfield-Arroyo, MD
- Calendar frame: modern shifted

- Visit type: Sick Visit
- Services: Problem-oriented office visit, established patient

## Chief complaint

Runny nose, sore throat and a dry cough for three days, twelve days after the second cycle. **S**

## History of present illness

Mr. Owens called the oncology line on day 13 of his second cycle of nivolumab with carboplatin and pemetrexed and was seen the same day, as his warning list asks for any new cough. Three days ago he developed a runny nose and a scratchy throat, and since yesterday a dry cough, worst at night. Several children at a youth club where he spoke last week had colds. His highest temperature at home was 37.8 °C last night. He has no breathlessness: he walked his usual 3 km this morning, a little slower. He has no chest pain, no blood in his sputum, no diarrhea and no rash. He has not smoked since the first cycle and has had no urge to with the cough. He takes varenicline twice daily and had his dexamethasone only around the infusion. He is worried that the cough means the immunotherapy is affecting his lungs. **S**

| Element | Detail |
|---|---|
| Onset | Three days ago, after a youth club visit where several children had colds |
| Severity | Dry cough, worse at night; no breathlessness at rest or on his morning walk |
| Context | Day 13 of cycle 2 of nivolumab with carboplatin and pemetrexed |
| Associated signs and symptoms | Runny nose, sore throat, temperature up to 37.8 °C; no chest pain, hemoptysis, diarrhea or rash |
| Modifying factors | Honey and warm drinks help the throat |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Low-grade temperature to 37.8 °C; tired; no rigors |
| Ears, nose, mouth, and throat | Positive | Runny nose and sore throat; no mouth sores |
| Respiratory | Positive | Dry cough for a day; no breathlessness, wheeze or hemoptysis |
| Cardiovascular | Negative | No chest pain, palpitations or leg swelling |
| Gastrointestinal | Negative | No diarrhea or abdominal pain |
| Integumentary | Negative | No rash or itching |

6 systems reviewed. **S**

## Current medications

- Varenicline 1 mg oral tablet, one tablet by mouth twice daily after food, for 12 weeks and then a further 12 weeks to prevent relapse **S**
- Nivolumab 360 mg intravenous infusion over 30 minutes on day 1 of each 21-day cycle, for three cycles before surgery (one 240 mg and one 120 mg vial) **S**
- Carboplatin 10 mg/mL injection, 525 mg (AUC 5 by the Calvert formula, creatinine clearance 80 mL/min) intravenously on day 1 of each 21-day cycle, for three cycles **S**
- Pemetrexed 500 mg/m2 (970 mg for a body surface area of 1.94 m2) intravenously over 10 minutes on day 1 of each 21-day cycle, for three cycles **S**
- Folic acid 1 mg oral tablet, one tablet daily from one week before the first pemetrexed dose until three weeks after the last **S**
- Dexamethasone 4 mg oral tablet, one tablet twice daily on the day before, the day of and the day after each pemetrexed dose **S**
- Ondansetron 8 mg oral tablet, one tablet every 8 hours as needed for nausea during chemotherapy **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/78 mmHg; pulse 84 bpm; respirations 16/min; temperature 37.6 °C; oxygen saturation 96% on room air; weight 75.6 kg; BMI 23.9 kg/m². All vital signs are synthetic.

Hemoglobin: 13.1 g/dL (low); White cell count: 5.4 10*3/uL; Absolute neutrophil count: 3.2 10*3/uL; Platelets: 176 10*3/uL. All results are synthetic.

## Change since baseline

- Hemoglobin: 15.1 g/dL at baseline, 13.1 g/dL (low) at this visit **S**
- White cell count: 8.4 10*3/uL at baseline, 5.4 10*3/uL at this visit **S**
- Platelets: 262 10*3/uL at baseline, 176 10*3/uL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Comfortable, talking in full sentences; temperature 37.6 °C |
| Vital signs | Oxygen saturation 96 percent at rest, as at his earlier visits, and 95 percent after a 6-minute corridor walk; respiratory rate 16 |
| Head, eyes, ears, nose, and throat | Red throat without exudate; clear nasal discharge; no mouth ulcers |
| Neck | No tender or enlarged lymph nodes |
| Respiratory | Clear to auscultation throughout; no crackles or wheeze |
| Skin | No rash |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Acute viral upper respiratory infection during chemoimmunotherapy** (J06.9). A cold, with a respiratory panel positive for rhinovirus and negative for influenza, COVID-19 and RSV. A new cough on a checkpoint inhibitor must raise the question of immune-related pneumonitis; here the oxygen saturation is unchanged at rest and on walking, the lungs are clear and the chest X-ray shows no new opacity, so pneumonitis is not suspected and no steroid is needed. The neutrophil count is 3.2 and the temperature is low grade, so this is not a neutropenic fever and no antibiotic is needed. **S**
   - Rest, fluids, honey and saline nasal spray; acetaminophen for the sore throat if needed.
   - Call the 24-hour oncology line at once for a temperature of 38.0 °C or more, breathlessness, oxygen saturation below 94 percent on his home meter, chest pain, or a cough that keeps worsening after a week: that would need a CT of the chest for pneumonitis.
   - Cycle 3 as planned in nine days if he is recovering; the oncology team agreed.
2. **Left upper lobe adenocarcinoma, stage IIB, on chemoimmunotherapy before surgery** (C34.12). Two of three cycles given on schedule; the nodule looks smaller on today's X-ray. **S**
   - No change.
3. **Nicotine dependence, on varenicline** (F17.210). Still not smoking after nearly five weeks, even with the cough. **S**
   - Continue varenicline 1 mg twice daily.

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026), National Comprehensive Cancer Network
- Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021), American Society of Clinical Oncology

## Follow-up

- Nurse telephone call in two days. Cycle 3 in nine days. Call the oncology line for any warning sign. **S**
- Next scheduled visit 2026-08-05: after three cycles: restaging CT, decision for lobectomy, thyroid result and surgical preparation. **S**
